Sequent Medical Inc. and Collaborators Presented Key Data Using a Novel Sequencing Technology to Predict Clinical Relapse

Published: Dec 13, 2011

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc., announced at the annual meeting of the American Society of Hematology (ASH) the results from several studies showing the sensitivity and specificity of the company’s Immune Cell Receptor Sequencing (ICRS) platform in detecting Minimal Residual Disease (MRD) and predicting clinical relapse in childhood and adult Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) patient samples.

Back to news